Research & Development Services was Equillium’s largest product and service line in fiscal 2024, bringing in $28.30M of $41.10M (69%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Research & Development Services | $11.80M | $27.00M | $28.30M |
| Upfront Payment Amortization | $4.00M | $9.10M | $12.80M |
| Total | $15.80M | $36.10M | $41.10M |
Equillium brought in $41.10M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. That was up 13.9% from $36.10M in fiscal 2023. Research & Development Services was the largest at $28.30M (68.9%), ahead of Upfront Payment Amortization at $12.80M (31.1%).
Compared with fiscal 2023, Upfront Payment Amortization grew 40.7% to $12.80M and Research & Development Services grew 4.8% to $28.30M. From fiscal 2022 to 2024, combined revenue from these lines grew from $15.80M to $41.10M, a compound annual growth rate of 61.3%. Research & Development Services' share of the total fell from 74.7% to 68.9%.
Equillium (EQ) reports its revenue by product and service. In fiscal 2024, Research & Development Services was its largest product and service line, bringing in $28.30M (68.9% of the total), followed by Upfront Payment Amortization at $12.80M (31.1%).
Research & Development Services was Equillium's largest product and service line in fiscal 2024, bringing in $28.30M, or 68.9% of the $41.10M total across its two product and service lines.
Upfront Payment Amortization grew faster than Research & Development Services in fiscal 2024, up 40.7% from $9.10M to $12.80M. Research & Development Services grew 4.8% to $28.30M.
Every figure comes from Equillium's annual financial filings, as reported. Each line keeps the name Equillium gives it, and years follow its fiscal calendar.
Equillium's revenue by product and service goes back to fiscal 2022, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.